Skip to content
#gene editing Open access

Belajar Tentang Agent Biologis -- Agent Biologis: A to Z

Sep 2026 · Zenodo (CERN European Organization for Nuclear Research)

Abstract

Mengapa buku ini dibutuhkan Terapi biologis berkembang pada pertemuan biologi molekuler, imunologi, genetika, biomaterial, manufaktur, uji klinis, regulasi, dan etik. Kompleksitas ini sering menimbulkan dua kesalahan ekstrem: menolak inovasi hanya karena belum familiar, atau menerima klaim hanya karena teknologi tampak canggih. Buku ini mengajarkan jalan tengah yang lebih ilmiah—antusias terhadap kemungkinan, tetapi disiplin terhadap definisi produk, mekanisme, mutu, bukti, dan keselamatan. Mahasiswa tidak diarahkan menghafal daftar platform. Mereka dilatih menjawab tujuh pertanyaan: apa produknya, bagaimana dibuat, apa dosisnya, ke mana produk pergi, target apa yang berubah, bukti apa yang mendukung manfaat, dan risiko apa yang tetap tidak pasti. Kerangka ini berlaku dari protein rekombinan sampai terapi sel dan gen. NAVIGASI BUKU / DAFTAR ISI Daftar Isi Peta navigasi ringkas menuju bagian awal, seluruh bab, dan lampiran BAGIAN AWAL Halaman penerbitan — Identitas dan batas penggunaan........................................................................... 2 Prakata — Mengapa buku ini dibutuhkan.............................................................................................. 3 Panduan belajar — Cara menggunakan buku......................................................................................... 6 Arsitektur — Kerangka berpikir lintas modalitas..................................................................................... 7 Orientasi — Capaian pembelajaran buku............................................................................................... 8 Peta buku — Alur kompetensi............................................................................................................. 9 Atlas visual — Enam keluarga modalitas biologis.................................................................................. 10 Kalibrasi bukti — Dari plausibilitas menuju nilai klinis........................................................................... 11 Istilah — Singkatan penting.............................................................................................................. 12 Kontrak epistemik — Tingkat kepastian.............................................................................................. 13 Edisi komprehensif — Cara membaca edisi revisi.................................................................................. 14 BAGIAN I • FONDASI 01 Lanskap Agen Biologis: Produk, Proses, dan Tingkat Kematangan Bukti.............................................. 15 02 Biologi Cedera, Penyembuhan, Fibrosis, dan Regenerasi Endogen....................................................... 46 03 Protein Terapeutik, Antibodi, Sitokin, dan Growth Factors................................................................ 77 04 Activated Growth Factor dan Konsentrat Platelet: PRP, PRF, CGF..................................................... 108 NAVIGASI BUKU / DAFTAR ISI Daftar Isi • Lanjutan BAGIAN II • PLATFORM 05 Stem Cell States, Potency, Niche, dan Platform Sel.......................................................................... 140 06 Manufaktur Terapi Sel: Identity, Purity, Potency, dan Chain of Identity.............................................. 171 07 Terapi Sel: Engraftment, Replacement, dan Efek Parakrin................................................................ 202 08 Cellular Immunotherapy: CAR-T, TCR-T, NK, dan Vaksin Kanker.................................................... 233 09 Secretome, Conditioned Medium, Extracellular Vesicles, dan Cell Products......................................... 264 10 Gene Therapy, RNA Therapeutics, Genome Editing, dan Gene-Modified Cells..................................... 295 11 Tissue Engineering, Biomaterials, Scaffolds, dan 3D Biofabrication.................................................... 326 BAGIAN III • TRANSLASI 12 Nonclinical Development: Model, Dosis, Biodistribusi, dan Keselamatan............................................ 357 13 Clinical Development: FIH, Uji Efikasi, Endpoint, dan Appraisal Bukti............................................... 388 14 Regulasi, Bioetika, GMP, Komersialisasi, dan Akses........................................................................ 419 15 Capstone Integratif: Memilih Modalitas untuk Masalah Klinis.......................................................... 450 LAMPIRAN A Checklist appraisal universal....................................................................................................... 481 B Template target product profile.................................................................................................... 482 C Rubrik jawaban ilmiah dan presentasi kasus................................................................................... 483 D1 Bank soal integratif 1–5............................................................................................................. 484 D2 Bank soal integratif 6–10........................................................................................................... 485 E Pedoman jawaban bank soal integratif........................................................................................... 486 F1 Glosarium inti A–M................................................................................................................. 487 F2 Glosarium inti N–Z.................................................................................................................. 488 G Protokol pembaruan buku.......................................................................................................... 489 H Daftar sumber resmi tambahan.................................................................................................... 490 PANDUAN BELAJAR Cara menggunakan buku agar cepat memahami 1. Mulai dari pembuka kasus dan tuliskan hipotesis sebelum membaca penjelasan. 2. Gunakan peta konsep untuk mengikuti urutan produk–paparan–target–respons–outcome. 3. Baca tabel sebagai alat perbandingan, bukan sebagai daftar hafalan. 4. Kerjakan retrieval prompt tanpa melihat teks, lalu periksa alasan pada kunci jawaban. 5. Tandai klaim yang masih preklinik, investigasional, off-label, atau belum terbukti. 6. Ulangi latihan dengan mengganti indikasi, populasi, proses, atau rute untuk menguji transfer belajar. METODE 20–5–2 Baca 20 menit, tutup buku dan tulis lima konsep, lalu jelaskan dua hubungan kausal dengan bahasa sendiri.

View source

Similar papers

#computer vision Conference Aug 2008

A Preliminary Roadmap for Empirical Research on Agile Software Development

Some claim that especially in the field of agile software development the research lags years behind of the practice. In this paper, we characterize the status and main challenges for research on agile software development, and propose a preliminary roadmap, focusing on providing more empirical research, primarily on experienced agile teams and organizations, connecting better to existing streams of research in more established fields, giving more attention to management-oriented approaches, and finally give more emphasis to the core ideas in agile software development in order to increase our understanding. We hope that this preliminary roadmap serves as a starting point for creating a common research agenda and enables the generation of fruitful discussions and research results from the field.

Torgeir Dingsøyr, T. Dybå, P. Abrahamsson · 92 citations · ⚡7
#computer vision Book Open access Mar 2017

On the Unhappiness of Software Developers

The results indicate that software developers are a slightly happy population, but the need for limiting the unhappiness of developers remains, and 219 factors representing causes of unhappiness while developing software are identified.

D. Graziotin, Fabian Fagerholm, Xiaofeng Wang et al. · 84 citations · ⚡6
#computer vision Open access Feb 2018

Lean Internal Startups for Software Product Innovation in Large Companies: Enablers and Inhibitors

This study investigates how Lean internal startup facilitates software product innovation in large companies and identifies its enablers and inhibitors, and shows the potential of the method-in-action framework to investigate the Lean startup approach in non-startup context.

Henry Edison, Nina M. Smørsgård, Xiaofeng Wang et al. · 78 citations · ⚡6
#computer vision Review Apr 2024

AI-powered Code Review with LLMs: Early Results

The goal is to not only refine the accuracy of the LLM-based tool but also to underscore its potential in streamlining the software development lifecycle through proactive code improvement and education.

Z. Rasheed, Malik Abdul Sami, Muhammad Waseem et al. · 62 citations · ⚡3
#computer vision Conference Aug 2008

Scrum in a Multiproject Environment: An Ethnographically-Inspired Case Study on the Adoption Challenges

Agile methods continue to gain popularity. In particular, the Scrum method appears to be on the verge of becoming a de-facto standard in the industry, leading the so called Agile movement. While there are success stories and recommendations, there is little scientifically valid evidence of the challenges in the adoption of Agile methods in general, and Scrum in particular. Little, if anything, is empirically known about the application and adoption of Scrum in a multi-team and multi-project situation. The authors carried out an ethnographically informed longitudinal case study in industrial settings and closely followed how the Scrum method was adopted in a 20-person department, working in a simultaneous multi-project R&D environment. Altogether 10 challenges pertinent to the case of multi-team multi-project Scrum adoption were identified in the study. The authors contend that these results carry great relevance for other industrial teams. Future research avenues arising from the study are indicated.

A. Marchenko, P. Abrahamsson · 59 citations · ⚡11

Related blog posts

GPT-Lab Sep 17, 2026

Beyond Prompt Engineering: The Role of Tacit Knowledge in Software Engineering

AI is making software generation faster, but speed does not remove the need for expertise. As more work is delegated to AI, tacit knowledge may become one of the most important human advantages in software engineering. The post Beyond Prompt Engineering: The Role of Tacit Knowledge in Software Engineering appeared first on GPT-Lab.

MIT News · Artificial Intelligence Sep 14, 2026

New method enables AI for safety-critical situations

The “HardFlow” algorithm could help generative AI models produce high-quality outputs that obey strict requirements when “pretty close” doesn’t cut it.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.